Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2025 ARTÍCULOS , VIENDO DEL 1516 AL 1530

To know or to not know: The importance of assessing awareness of cognitive function in the early stages of Alzheimer's disease

Vannini P, Zamboni G.

J Alzheimers Dis. 2025 Aug;106(3):911-914. doi: 10.1177/13872877251350138. Epub 2025 Jun 16.

Grey-Matter Structure Markers of Alzheimer's Disease, Alzheimer's Conversion, Functioning and Cognition: A Meta-Analysis Across 11 Cohorts

Couvy-Duchesne B, Frouin V, Bouteloup V, Koussis N, Sidorenko J, Jiang J, Wink AM, Lorenzini L, Barkhof F, Trollor JN, Mangin JF, Sachdev PS, Brodaty H, Lupton MK, Breakspear M, Colliot O, Visscher PM, Wray NR; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle flagship study of ageing; Alzheimer's Disease Repository Without Borders Investigators; MEMENTO cohort Study Group.

Hum Brain Mapp. 2025 Feb 1;46(2):e70089. doi: 10.1002/hbm.70089.

Nutritional interventions for preventing cognitive decline in patients with mild cognitive impairment and Alzheimer's disease: A comprehensive network meta-analysis and Mendelian Randomization study

He Q, Bennett AN, Zhang C, Zhang JY, Tong S, Chan KHK.

Clin Nutr ESPEN. 2025 Jun;67:555-566. doi: 10.1016/j.clnesp.2025.03.040. Epub 2025 Mar 25.

The effect of repetitive transcranial magnetic stimulation on immediate and long-term cognitive functions in Alzheimer's dementia and mild cognitive impairment: a meta-analysis

Wang B, Wang Y, Yang F, Han F, Li K, Sun K, Liang P.

J Neuroeng Rehabil. 2025 Dec 15;22(1):262. doi: 10.1186/s12984-025-01777-8.

Effectiveness of probiotic supplements on cognitive function in mild cognitive impairment and Alzheimer's disease: A meta-analysis of randomized controlled trials

Peng TR, Lin HH, Tseng TL, Wu TW.

Gen Hosp Psychiatry. 2025 Nov-Dec;97:284-293. doi: 10.1016/j.genhosppsych.2025.11.004. Epub 2025 Nov 11.

Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches

Bereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M.

J Prev Alzheimers Dis. 2025 Dec;12(10):100367. doi: 10.1016/j.tjpad.2025.100367. Epub 2025 Oct 27.

Salience and frontoparietal network impairments across disease stages in dementia with Lewy bodies: A comparative functional MRI study with Alzheimer's disease

Gabriel V, Chabran E, Sourty M, Cretin B, Philippi N, Muller C, Anthony P, Demuynck C, Loureiro de Sousa P, Botzung A, Sanna L, Bousiges O, Blanc F.

J Alzheimers Dis. 2025 Dec;108(3):1398-1409. doi: 10.1177/13872877251386844. Epub 2025 Oct 17.

Cognitive training for Alzheimer's disease and other forms of dementia: Insights from a systematic review and Bayesian meta-analysis

Giaquinto F, Iaia M, Rizzi E, Macchitella L, Romano DL, Tosi G, Angelelli P.

J Alzheimers Dis. 2025 Jun;105(4):1252-1274. doi: 10.1177/13872877251334795. Epub 2025 May 13.

Structural and metabolic topological alterations associated with butylphthalide treatment in mild cognitive impairment: Data from a randomized, double-blind, placebo-controlled trial

Han X, Gong S, Gong J, Wang P, Li R, Chen R, Xu C, Sun W, Li S, Chen Y, Yang Y, Luan H, Wen B, Guo J, Lv S, Wei C.

Psychiatry Clin Neurosci. 2025 Jun;79(6):336-343. doi: 10.1111/pcn.13812. Epub 2025 Mar 31.

The Biological Intersection Between Chemotherapy-Related Cognitive Impairment and Alzheimer Disease

Torre M, Zanella CA, Feany MB.

Am J Pathol. 2025 Nov;195(11):2088-2101. doi: 10.1016/j.ajpath.2024.12.013. Epub 2025 Jan 23.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.

The Everyday Function Intervention Trial (EFIT) protocol: A randomized clinical trial

Ross LA, Fine C, Stephan AT, Chai HW, McVey A, Phillips CB, Gamaldo A, Mogle J, Dennis N, Sliwinski M, Visscher K.

Contemp Clin Trials. 2025 May;152:107829. doi: 10.1016/j.cct.2025.107829. Epub 2025 Jan 30.

Risk of Alzheimer's disease in Down syndrome: Insights gained by multi-omics

Qu HQ, Liu Y, Connolly JJ, Mentch FD, Kao C, Hakonarson H.

Alzheimers Dement. 2025 Apr;21(4):e14604. doi: 10.1002/alz.14604.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis

Jeong SY, Suh CH, Lim JS, Shim WH, Heo H, Choi Y, Kim HS, Kim SJ, Lee JH.

Neurology. 2025 Apr 22;104(8):e213483. doi: 10.1212/WNL.0000000000213483. Epub 2025 Mar 19.

Visuospatial impairment in dementia: a new index to improve the clinical diagnosis of Alzheimer's disease

Santagata F, Cappa SF, Presta R, Burgio C, Luppi C, Massaia M, Calvi E, D'Amelio P.

Aging Clin Exp Res. 2025 Apr 18;37(1):127. doi: 10.1007/s40520-025-03028-1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias